Arrowhead Pharmaceuticals, Inc. (0HI3.L)
| Previous close | 22.25 |
| Open | 22.28 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 22.00 - 22.28 |
| 52-week range | 20.75 - 41.86 |
| Volume | |
| Avg. volume | 1,779 |
| Market cap | 21.618M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.08 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireArrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
Business WireArrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.
Business WireArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.
